Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Must have received: immunomodulatory drug

prior treatments with antimyeloma therapy which must have included an immunomodulatory drug

Must have received: proteasome inhibitor

prior treatments with antimyeloma therapy which must have included ... proteasome inhibitor

Must have received: anti-CD38 treatment

prior treatments with antimyeloma therapy which must have included ... anti-CD38 treatment

Cannot have received: BCMA-targeting modalities

Exception: Phase 2a part only

For patient entering the Phase 2a part only: Prior treatment with any approved or experimental BCMA-targeting modalities are not allowed.

Cannot have received: autologous stem cell transplant

Exception: within 12 weeks before the first infusion or is planning for autologous SCT

Autologous or allogenic SCT within 12 weeks before the first infusion or is planning for autologous SCT.

Cannot have received: allogenic stem cell transplant

Exception: within 12 weeks before the first infusion

Autologous or allogenic SCT within 12 weeks before the first infusion

Cannot have received: radiation therapy

Exception: within 21 days prior to the first study treatment infusion

Radiotherapy within 21 days prior to the first study treatment infusion.